Arrowhead Pharmaceuticals, Inc. Share Price
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.09 USD | -2.75% |
|
-6.19% | +10.09% |
| Capitalization | 10.3B 8.92B 8.18B 7.7B 14.34B 981B 14.56B 97.24B 37.84B 474B 38.66B 37.82B 1,650B | P/E ratio 2026 * |
-23.1x | P/E ratio 2027 * | -17.9x |
|---|---|---|---|---|---|
| Enterprise value | 9.32B 8.07B 7.4B 6.96B 12.97B 888B 13.17B 87.98B 34.24B 429B 34.98B 34.22B 1,493B | EV / Sales 2026 * |
21x | EV / Sales 2027 * | 27.9x |
| Free-Float |
94.46% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Arrowhead Pharmaceuticals, Inc.
| 1 day | -2.75% | ||
| 1 week | -6.19% | ||
| Current month | -6.19% | ||
| 1 month | -7.64% | ||
| 3 months | +22.18% | ||
| 6 months | +18.96% | ||
| Current year | +10.09% |
| 1 week | 69.3 |  | 77.18 |
| 1 month | 69.3 | | 82.26 |
| Current year | 54.02 | | 82.26 |
| 1 year | 14.3 | | 82.26 |
| 3 years | 9.57 | | 82.26 |
| 5 years | 9.57 | | 93.66 |
| 10 years | 1.2 | | 93.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 30/11/2007 | |
Daniel Apel
DFI | Director of Finance/CFO | - | 12/05/2025 |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | - | |
Mauro Ferrari
BRD | Director/Board Member | 66 | 18/08/2010 |
Michael Perry
BRD | Director/Board Member | 66 | 18/12/2011 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-11 | Sell | Director | -2,970 | 0.0021% | ||
| 03-04 | Sell | Chief Technology Officer | 10,000 | 0.0071% | ||
| 01-05 | Don | Chief Operating Officer | 77,500 | 0.0571% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.75% | -6.19% | +334.80% | +102.35% | 10.3B | |
| +5.10% | +7.04% | +48.39% | +103.29% | 55.01B | |
| -0.20% | -4.96% | +50.88% | +49.82% | 43.37B | |
| -1.69% | -8.20% | -18.81% | -19.82% | 22.27B | |
| -10.20% | -11.87% | +27.98% | +384.17% | 20.42B | |
| +0.99% | -1.80% | +32.82% | -24.48% | 17.27B | |
| +3.90% | -7.07% | +9.55% | -42.27% | 15.02B | |
| +0.40% | +4.40% | +22.47% | +169.98% | 13.25B | |
| +0.82% | -14.85% | +16.25% | - | 11.71B | |
| -0.47% | -15.79% | -28.27% | +645.96% | 11.46B | |
| Average | -0.41% | -5.75% | +49.61% | +152.11% | 22.01B | |
| Weighted average by Cap. | +0.38% | -3.09% | +42.45% | +119.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 444M 385M 353M 332M 618M 42.32B 628M 4.19B 1.63B 20.47B 1.67B 1.63B 71.18B | 337M 292M 268M 252M 469M 32.09B 476M 3.18B 1.24B 15.52B 1.26B 1.24B 53.97B |
| Net income | -449M -389M -357M -336M -625M -42.78B -635M -4.24B -1.65B -20.69B -1.69B -1.65B -71.95B | -592M -513M -471M -443M -825M -56.43B -837M -5.59B -2.18B -27.29B -2.22B -2.17B -94.9B |
| Net Debt | -980M -849M -779M -733M -1.36B -93.38B -1.39B -9.26B -3.6B -45.16B -3.68B -3.6B -157B | -905M -784M -719M -677M -1.26B -86.24B -1.28B -8.55B -3.33B -41.71B -3.4B -3.32B -145B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/06/26 | 73.09 $ | -2.75% | 1,227,876 |
| 04/06/26 | 75.16 $ | +3.60% | 1,130,307 |
| 03/06/26 | 72.55 $ | +2.44% | 1,484,570 |
| 02/06/26 | 70.82 $ | -5.82% | 2,010,116 |
| 01/06/26 | 75.20 $ | -3.48% | 2,287,832 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ARWR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition